Hepatitis B cost-effectiveness of therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Given the risk of complications (e.g., cirrhosis or hepatocellular carcinoma) in infants and young children who are infected with the HBV, as well as the benefits of vaccination and postexposure prophylaxis, the prevention and treatment of hepatitis B are considered cost-effective.[1]
References
- ↑ “Hepatitis B” (PDF).
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH